BSX vs EW
BSX: A global medical-device innovator developing minimally invasive solutions for cardiovascular, rhythm management, and endoscopic procedures. EW: Global leader in transcatheter heart valve therapies and structural heart repair technologies, treating the world's leading cause of death with minimally invasive solutions.
Side-by-side fundamentals
| Metric | BSX | EW | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $43.04 | $87.27 | |
| Market cap as of 2026-07-16 | $64.5B | $50.9B | |
| P/E as of 2026-07-16 | 18.09 | 46.42 | BSX lower |
| PEG as of 2026-07-16 | 0.24 | 2.13 | BSX lower |
| Net margin as of 2026-07-16 | +17.3% | +17.4% | EW higher |
| Gross margin as of 2026-07-16 | +69.1% | +77.9% | EW higher |
| Operating margin as of 2026-07-16 | +18.4% | +17.1% | BSX higher |
| ROE as of 2026-07-16 | +14.9% | +10.6% | BSX higher |
| ROA as of 2026-07-16 | +8.3% | +8.2% | BSX higher |
| Debt / equity as of 2026-07-16 | 0.43 | 0.06 | EW lower |
| Revenue growth (YoY) as of 2026-07-16 | +17.4% | +13.8% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +10.8% | BSX higher |
| Dividend yield as of 2026-07-16 | +0.0% | n/a | |
| Beta as of 2026-07-16 | 0.58 | 0.83 | |
| 1-year return as of 2026-07-15 close | -59.1% | +15.1% | EW higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.